NovoCure (NVCR) Free Cash Flow (QoQ) (2015 - 2026)
NovoCure (NVCR) Free Cash Flow (QoQ) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.86 Bn | 176.56 Bn | 6.27 Bn |
| 2 | Stryker | 128.65 Bn | 125.78 Bn | 3.81 Bn |
| 3 | Medtronic | 108.75 Bn | 99.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.34 Bn | 66.89 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.33 Bn | 44.65 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.35 Bn | 26.07 Bn | 1.98 Bn |
| 7 | Dexcom | 28.33 Bn | 27.21 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.90 Bn | 26.32 Bn | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn |
| 10 | NovoCure | 2.01 Bn | 1.57 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 106.51% |
| Mar 31, 2026 | 18.48% |
| Dec 31, 2025 | -253.50% |
| Sep 30, 2025 | 169.64% |
| Jun 30, 2025 | 53.71% |
| Mar 31, 2025 | -273.40% |
| Dec 31, 2024 | -3,936.81% |
| Sep 30, 2024 | 97.67% |
| Jun 30, 2024 | 69.63% |
| Mar 31, 2024 | -102.81% |
| Dec 31, 2023 | 19.53% |
| Sep 30, 2023 | 10.45% |
| Jun 30, 2023 | -30.04% |
| Mar 31, 2023 | -125.04% |
| Dec 31, 2022 | -160.64% |
| Sep 30, 2022 | 43.73% |
| Jun 30, 2022 | 232.47% |
| Mar 31, 2022 | -6,853.85% |
| Dec 31, 2021 | -99.38% |
| Sep 30, 2021 | -10.41% |